BridgeBio Pharma BBIO Contract Liabilities
Contract Liabilities at other companies
Segments
By product
See fullOther financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is BridgeBio Pharma's contract liabilities?
- BridgeBio Pharma (BBIO) reported contract liabilities of $11.78M in Q1 2026.
- What does contract liabilities mean?
- Money received from customers for goods or services that have not yet been delivered.
- How do you interpret contract liabilities?
- An increase suggests strong future revenue visibility, while a decrease may indicate faster fulfillment or slowing sales bookings.
- How does contract liabilities compare across companies?
- Common in biotech companies with collaboration or licensing agreements involving upfront payments.